<?xml version='1.0' encoding='utf-8'?>
<document id="17524230"><sentence text="Transport characteristics of zolmitriptan in a human intestinal epithelial cell line Caco-2."><entity charOffset="29-41" id="DDI-PubMed.17524230.s1.e0" text="zolmitriptan" /></sentence><sentence text="The intestinal absorption characteristics and the efflux mechanisms of zolmitriptan, a new generation and highly selective 5-HT(1B/1D) receptor agonist used in the acute oral treatment of migraine, were investigated"><entity charOffset="71-83" id="DDI-PubMed.17524230.s2.e0" text="zolmitriptan" /></sentence><sentence text=" A human intestinal cell line, Caco-2, was used as an in-vitro model of the intestinal mucosa to assess transepithelial transport of zolmitriptan"><entity charOffset="133-145" id="DDI-PubMed.17524230.s3.e0" text="zolmitriptan" /></sentence><sentence text=" In the Caco-2 cells, the absorptive transport of zolmitriptan was pH dependent and the transport was enhanced at weakly alkali pH on the apical side"><entity charOffset="50-62" id="DDI-PubMed.17524230.s4.e0" text="zolmitriptan" /></sentence><sentence text=" No concentration dependence and saturation were observed for the apical-to-basolateral and basolateral-to-apical transport of zolmitriptan at a concentration of 0"><entity charOffset="127-139" id="DDI-PubMed.17524230.s5.e0" text="zolmitriptan" /></sentence><sentence text="1-10 mM" /><sentence text=" The permeability ratio value was about 1" /><sentence text="5-2" /><sentence text="6 at a concentration of 0" /><sentence text="1-2" /><sentence text="0 mM" /><sentence text=" Inhibition experiments using verapamil, nifedipine and nimodipine as inhibitors were studied and indicated that P-glycoprotein participated in the transport of zolmitriptan"><entity charOffset="30-39" id="DDI-PubMed.17524230.s12.e0" text="verapamil" /><entity charOffset="41-51" id="DDI-PubMed.17524230.s12.e1" text="nifedipine" /><entity charOffset="56-66" id="DDI-PubMed.17524230.s12.e2" text="nimodipine" /><entity charOffset="161-173" id="DDI-PubMed.17524230.s12.e3" text="zolmitriptan" /><pair ddi="false" e1="DDI-PubMed.17524230.s12.e0" e2="DDI-PubMed.17524230.s12.e0" /><pair ddi="false" e1="DDI-PubMed.17524230.s12.e0" e2="DDI-PubMed.17524230.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17524230.s12.e0" e2="DDI-PubMed.17524230.s12.e2" /><pair ddi="false" e1="DDI-PubMed.17524230.s12.e0" e2="DDI-PubMed.17524230.s12.e3" /><pair ddi="false" e1="DDI-PubMed.17524230.s12.e1" e2="DDI-PubMed.17524230.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17524230.s12.e1" e2="DDI-PubMed.17524230.s12.e2" /><pair ddi="false" e1="DDI-PubMed.17524230.s12.e1" e2="DDI-PubMed.17524230.s12.e3" /><pair ddi="false" e1="DDI-PubMed.17524230.s12.e2" e2="DDI-PubMed.17524230.s12.e2" /><pair ddi="false" e1="DDI-PubMed.17524230.s12.e2" e2="DDI-PubMed.17524230.s12.e3" /></sentence><sentence text=" Inhibition of the Na+-H+ exchanger with amiloride resulted in a significant increase in absorption and a slight inhibition in secretion"><entity charOffset="19-25" id="DDI-PubMed.17524230.s13.e0" text="Na+-H+" /><entity charOffset="41-50" id="DDI-PubMed.17524230.s13.e1" text="amiloride" /><pair ddi="false" e1="DDI-PubMed.17524230.s13.e0" e2="DDI-PubMed.17524230.s13.e0" /><pair ddi="false" e1="DDI-PubMed.17524230.s13.e0" e2="DDI-PubMed.17524230.s13.e1" /></sentence><sentence text=" This suggests that the Na+-H+ exchanger may be involved in the transport of zolmitriptan"><entity charOffset="24-30" id="DDI-PubMed.17524230.s14.e0" text="Na+-H+" /><entity charOffset="77-89" id="DDI-PubMed.17524230.s14.e1" text="zolmitriptan" /><pair ddi="false" e1="DDI-PubMed.17524230.s14.e0" e2="DDI-PubMed.17524230.s14.e0" /><pair ddi="false" e1="DDI-PubMed.17524230.s14.e0" e2="DDI-PubMed.17524230.s14.e1" /></sentence><sentence text=" The results indicated that the transport of zolmitriptan was mediated by both passive diffusion and active transport"><entity charOffset="45-57" id="DDI-PubMed.17524230.s15.e0" text="zolmitriptan" /></sentence><sentence text=" A series of drug-drug interaction experiments were carried out between zolmitriptan and some drugs that may be co-administrated with zolmitriptan in the clinic"><entity charOffset="72-84" id="DDI-PubMed.17524230.s16.e0" text="zolmitriptan" /><entity charOffset="134-146" id="DDI-PubMed.17524230.s16.e1" text="zolmitriptan" /><pair ddi="false" e1="DDI-PubMed.17524230.s16.e0" e2="DDI-PubMed.17524230.s16.e0" /><pair ddi="false" e1="DDI-PubMed.17524230.s16.e0" e2="DDI-PubMed.17524230.s16.e1" /></sentence><sentence text=" The results indicated that flunarizine, cetirizine, propranolol and atenolol potently decreased both the apical-to-basolateral and basolateral-to-apical transport rate of zolmitriptan"><entity charOffset="28-39" id="DDI-PubMed.17524230.s17.e0" text="flunarizine" /><entity charOffset="41-51" id="DDI-PubMed.17524230.s17.e1" text="cetirizine" /><entity charOffset="53-64" id="DDI-PubMed.17524230.s17.e2" text="propranolol" /><entity charOffset="69-77" id="DDI-PubMed.17524230.s17.e3" text="atenolol" /><entity charOffset="172-184" id="DDI-PubMed.17524230.s17.e4" text="zolmitriptan" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e0" e2="DDI-PubMed.17524230.s17.e0" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e0" e2="DDI-PubMed.17524230.s17.e1" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e0" e2="DDI-PubMed.17524230.s17.e2" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e0" e2="DDI-PubMed.17524230.s17.e3" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e0" e2="DDI-PubMed.17524230.s17.e4" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e1" e2="DDI-PubMed.17524230.s17.e1" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e1" e2="DDI-PubMed.17524230.s17.e2" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e1" e2="DDI-PubMed.17524230.s17.e3" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e1" e2="DDI-PubMed.17524230.s17.e4" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e2" e2="DDI-PubMed.17524230.s17.e2" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e2" e2="DDI-PubMed.17524230.s17.e3" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e2" e2="DDI-PubMed.17524230.s17.e4" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e3" e2="DDI-PubMed.17524230.s17.e3" /><pair ddi="false" e1="DDI-PubMed.17524230.s17.e3" e2="DDI-PubMed.17524230.s17.e4" /></sentence><sentence text=" Cimetidine and aspirin slightly inhibited the apical-to-basolateral transport of zolmitriptan, but significantly decreased the basolateral-to-apical transport of zolmitriptan"><entity charOffset="1-11" id="DDI-PubMed.17524230.s18.e0" text="Cimetidine" /><entity charOffset="16-23" id="DDI-PubMed.17524230.s18.e1" text="aspirin" /><entity charOffset="82-94" id="DDI-PubMed.17524230.s18.e2" text="zolmitriptan" /><entity charOffset="163-175" id="DDI-PubMed.17524230.s18.e3" text="zolmitriptan" /><pair ddi="false" e1="DDI-PubMed.17524230.s18.e0" e2="DDI-PubMed.17524230.s18.e0" /><pair ddi="false" e1="DDI-PubMed.17524230.s18.e0" e2="DDI-PubMed.17524230.s18.e1" /><pair ddi="false" e1="DDI-PubMed.17524230.s18.e0" e2="DDI-PubMed.17524230.s18.e2" /><pair ddi="false" e1="DDI-PubMed.17524230.s18.e0" e2="DDI-PubMed.17524230.s18.e3" /><pair ddi="false" e1="DDI-PubMed.17524230.s18.e1" e2="DDI-PubMed.17524230.s18.e1" /><pair ddi="false" e1="DDI-PubMed.17524230.s18.e1" e2="DDI-PubMed.17524230.s18.e2" /><pair ddi="false" e1="DDI-PubMed.17524230.s18.e1" e2="DDI-PubMed.17524230.s18.e3" /><pair ddi="false" e1="DDI-PubMed.17524230.s18.e2" e2="DDI-PubMed.17524230.s18.e2" /><pair ddi="false" e1="DDI-PubMed.17524230.s18.e2" e2="DDI-PubMed.17524230.s18.e3" /></sentence><sentence text=" Thus, the absorption drug-drug interactions should be considered when these drugs are co-administrated with zolmitriptan in the clinic"><entity charOffset="109-121" id="DDI-PubMed.17524230.s19.e0" text="zolmitriptan" /></sentence><sentence text="" /></document>